Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03935555
Title Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Samus Therapeutics, Inc.
Indications

myelofibrosis

Therapies

PU-H71

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.